
A truth serum for cancer — microRNAs have major poten-tial as cancer biomarkers
Lena J Chin 1, Frank J Slack 1
Department of Molecular, Cellular and Developmental Biology, Yale University, PO Box 208103, New Haven, CT 06520, USA
Correspondence: Frank J Slack, E-mail:frank.slack@yale.edu
1
Cell Research (2008) 18:983-984. doi: 10.1038/cr.2008.290; published online 2 October 2008
Identification of biological markers of cancer is a major area of research. Biomarkers could identify the presence of a tumor before it could otherwise be easily detected, and the ability to detect cancers at early stages is a key factor in increasing survivability. For example, the American Cancer Society finds that a reason breast cancer survival rates are so high is that there are good methods for early detection of tumors. However, this is not the case for most cancers. For lung cancer, the five-year survival is 15%, but for the 16% of lung cancer cases diagnosed at early stages, the five-year survival rate is 49% [1]. While this is just one example, the abil-ity to identify a cancer while it is still localized is clearly beneficial. Currently, most methods for discovering and test-ing tumor biomarkers are difficult and labor-intensive procedures, and at most, only several markers can be tested for at one time. However, due to the simplicity of getting a blood sample, easily testable biomarkers found in blood serum would be especially useful.
Just recently, scientists have begun identifying microRNAs (miRNAs) as cancer biomarkers [2-4]. MiRNA genes code for a relatively new class of regulatory RNAs that are ~22 nucleo-tides long. miRBase (Release 12.0), the central database for miRNAs, lists over 8 000 miRNAs from plants, animals and viruses. Many miRNAs are well conserved across species,

suggesting an important role for them. MiRNA biogenesis and regulation of gene expression have been exten-sively covered in numerous reviews [5-7]. Briefly, most mature miRNAs are the products of RNA polymerase II-transcribed transcripts that have been processed by two RNase III enzymes, Drosha and Dicer. The mature miRNA is incorporated into an RNA-induced silencing complex that binds to a target messenger RNA (mRNA). In animals, miRNAs bind with imperfect comple-mentarity to the 3′ untranslated region of their targets to inhibit gene expression through several possible mechanisms, including degradation of the mRNA, inhibition of the initiation or elongation steps of translation, and localization to cytoplasmic P-bodies. Because animal miRNAs bind with imperfect comple-mentarity, miRNAs are though to be capable of targeting numerous mRNAs; thus, misexpression of one miRNA can disrupt the expression of hundreds of proteins.
Although first discovered in C. el-egans, miRNAs have since been shown to be involved in human cancers [5]. A number of miRNA genes were shown to be located in fragile regions of the human genome that are associated with cancer [8]. Furthermore, miRNAs are continuously being shown to act as both oncogenes and tumor suppressors [5]. With the development of technolo-gies to look at the expression levels of hundreds of miRNAs at a time and the clear role of miRNAs in cancers, groups began looking at miRNA profiles of dif-ferent cancers. Calin et al. were the first to show that their microRNA microar-ray could differentiate between B cell chronic lymphocyte leukemia (CLL) cells and normal cells. Furthermore, they classified CLL samples into two different groups based on their miRNA profiles, and these profiles corresponded to high or low levels of a protein that is associated with a positive prognosis at low levels [9]. Shortly after, Lu et al. developed a method for bead-based miRNA profiling that they found to be more sensitive since the hybridizations were taking place in solution. Employ-ing this technique on twenty different cancers, they found that each cancer had a specific miRNA profile and that most poorly differentiated tumors could be classified to their tissues of origin based on their miRNA expression levels [10]. Through various techniques, numerous groups have gone on to show that dif-ferent cancer types have distinct miRNA profiles. Cancer-specific miRNA signa-tures can be useful for classifying tumor origin of poorly differentiated tumors, and being able to determine the tissue of origin of these tumors may be valu-able in determining a patient’s course of treatment.
While cancer-specific miRNAs are also important for shedding light onto the molecular basis of cancer, being
A truth serum for cancer... 2页 2财富值 MicroRNAs_ Potential bio... ...These molecules have become recognized as one of the major regulatory gate...
A truth serum for canc... 2页 1下载券 ... miR-337-3p and miR-378) as potential ...c microRNAs are useful to distinguish cancer ...
MicroRNAs_ Novel Biomark... 暂无评价 9页 2... A truth serum for cancer... 2页 2财富值 ...potential agents for clinical diagnostics as well ...
Cardiovascular biomark... 暂无评价 6页 免费 ... A truth serum for canc... 2页 2财富值... Circulating MicroRNAs as Biomarkers and Potential ...
2010-Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers_... .Circulating MicroRNAs... 暂无评价 6页 免费 Signature of Circulati... ...
MicroRNAs_ Novel Biomark... 暂无评价 9页 2...et al analyzed serum microRNAs from lung cancer....potential as novel noninvasive molecular markers for...
A truth serum for cancer... 2页 2财富值 MicroRNAs as novel regul......[19] reported that miR-21 has the potential as a diagnostic biomarker for...
A truth serum for cancer... 2页 2财富值 Kinin Receptor Antagonis... ... Priority Report MicroRNAs as Potential Agents to Alter Resistance to ...
MicroRNAs_ Novel Biomark... 暂无评价 9页 2财富值 Expression of 6 Micro...If such an association is confirmed, it might provide a potential ...
Serum microRNAs as a nov... 5页 免费 ...potential function of miRNAs in cancer pathogenesis...as cancer therapeutic tools and miRNA therapy for...
热门文档